drulletje drie schreef op 7 februari 2018 13:56:
[...]
Deze kwam voorbij
Ying Huang - Bank of America Merrill Lynch
Hi. Thanks for taking the question. Maybe a quick one for Norbert. I didn't see you including on the filgotinib male subject safety study in the timeline for 2018 to 2019, the slide deck. And then secondly, maybe another question on the pricing dynamics in HIV market. After you launch B/F/TAF in the U.S., do you expect your competitor GSK to use pricing as a potential weapon to keep its share? Thank you.
Norbert W. Bischofberger - Gilead Sciences, Inc.
Yes, Ying. Thanks for the question. That's very observant of you that you have not seen the study. Yes, so we are performing a safety study. As you know, there was a safety signal in pre-clinical studies and in order to justify the 200 milligram dose, which is the higher dose that we're using in this study, we were asked by FDA to perform this study. So the study is enrolling and the reason why we don't have any timelines in it is simply we don't know yet. It's too early. So we have sites up and running. It's somewhat slow, always at the start. We just simply, it's impossible to predict what the exact timelines are.